BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 17547726)

  • 1. Pulmonary arterial hypertension in systemic sclerosis: the need for early detection and treatment.
    Proudman SM; Stevens WM; Sahhar J; Celermajer D
    Intern Med J; 2007 Jul; 37(7):485-94. PubMed ID: 17547726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis.
    Allanore Y; Borderie D; Avouac J; Zerkak D; Meune C; Hachulla E; Mouthon L; Guillevin L; Meyer O; Ekindjian OG; Weber S; Kahan A
    Arthritis Rheum; 2008 Jan; 58(1):284-91. PubMed ID: 18163505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension.
    Williams MH; Handler CE; Akram R; Smith CJ; Das C; Smee J; Nair D; Denton CP; Black CM; Coghlan JG
    Eur Heart J; 2006 Jun; 27(12):1485-94. PubMed ID: 16682379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease.
    Launay D; Mouthon L; Hachulla E; Pagnoux C; de Groote P; Remy-Jardin M; Matran R; Lambert M; Queyrel V; Morell-Dubois S; Guillevin L; Hatron PY
    J Rheumatol; 2007 May; 34(5):1005-11. PubMed ID: 17444586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulmonary complications: one of the most challenging complications of systemic sclerosis.
    Wells AU; Steen V; Valentini G
    Rheumatology (Oxford); 2009 Jun; 48 Suppl 3():iii40-4. PubMed ID: 19487223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease.
    Trad S; Amoura Z; Beigelman C; Haroche J; Costedoat N; Boutin le TH; Cacoub P; Frances C; Wechsler B; Grenier P; Piette JC
    Arthritis Rheum; 2006 Jan; 54(1):184-91. PubMed ID: 16385514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma.
    Garin MC; Highland KB; Silver RM; Strange C
    J Rheumatol; 2009 Feb; 36(2):330-6. PubMed ID: 19208563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determinants of pulmonary arterial hypertension in scleroderma.
    Plastiras SC; Karadimitrakis SP; Kampolis C; Moutsopoulos HM; Tzelepis GE
    Semin Arthritis Rheum; 2007 Jun; 36(6):392-6. PubMed ID: 17204309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France.
    Hachulla E; de Groote P; Gressin V; Sibilia J; Diot E; Carpentier P; Mouthon L; Hatron PY; Jego P; Allanore Y; Tiev KP; Agard C; Cosnes A; Cirstea D; Constans J; Farge D; Viallard JF; Harle JR; Patat F; Imbert B; Kahan A; Cabane J; Clerson P; Guillevin L; Humbert M;
    Arthritis Rheum; 2009 Jun; 60(6):1831-9. PubMed ID: 19479881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization.
    Hsu VM; Moreyra AE; Wilson AC; Shinnar M; Shindler DM; Wilson JE; Desai A; Seibold JR
    J Rheumatol; 2008 Mar; 35(3):458-65. PubMed ID: 18203320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The presence of anti-centromere antibodies may predict progression of estimated pulmonary arterial systolic pressure in systemic sclerosis.
    Kampolis C; Plastiras S; Vlachoyiannopoulos P; Moyssakis I; Tzelepis G
    Scand J Rheumatol; 2008; 37(4):278-83. PubMed ID: 18612928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of exercise pulmonary arterial hypertension in scleroderma.
    Callejas-Rubio JL; Moreno-Escobar E; de la Fuente PM; Pérez LL; Fernández RR; Sánchez-Cano D; Mora JP; Ortego-Centeno N
    J Rheumatol; 2008 Sep; 35(9):1812-6. PubMed ID: 18634147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement.
    Steen V; Medsger TA
    Arthritis Rheum; 2003 Feb; 48(2):516-22. PubMed ID: 12571862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interstitial lung disease increases mortality in systemic sclerosis patients with pulmonary arterial hypertension without affecting hemodynamics and exercise capacity.
    Michelfelder M; Becker M; Riedlinger A; Siegert E; Drömann D; Yu X; Petersen F; Riemekasten G
    Clin Rheumatol; 2017 Feb; 36(2):381-390. PubMed ID: 28028682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving the detection of pulmonary hypertension in systemic sclerosis using pulmonary function tests.
    Schreiber BE; Valerio CJ; Keir GJ; Handler C; Wells AU; Denton CP; Coghlan JG
    Arthritis Rheum; 2011 Nov; 63(11):3531-9. PubMed ID: 21769839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies.
    Le Pavec J; Girgis RE; Lechtzin N; Mathai SC; Launay D; Hummers LK; Zaiman A; Sitbon O; Simonneau G; Humbert M; Hassoun PM
    Arthritis Rheum; 2011 Aug; 63(8):2456-64. PubMed ID: 21538327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulmonary function tests.
    Behr J; Furst DE
    Rheumatology (Oxford); 2008 Oct; 47 Suppl 5():v65-7. PubMed ID: 18784151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants of impairment in lung diffusing capacity in patients with systemic sclerosis.
    Guarnieri G; Zanatta E; Mason P; Scarpa MC; Pigatto E; Maestrelli P; Cozzi F
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S80-6. PubMed ID: 25897784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary arterial hypertension and severe pulmonary fibrosis in systemic sclerosis patients with a nucleolar antibody.
    Steen VD; Lucas M; Fertig N; Medsger TA
    J Rheumatol; 2007 Nov; 34(11):2230-5. PubMed ID: 17937469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive value of isolated DLCO reduction in systemic sclerosis patients without cardio-pulmonary involvement at baseline.
    Colaci M; Giuggioli D; Sebastiani M; Manfredi A; Lumetti F; Luppi F; Cerri S; Ferri C
    Reumatismo; 2015 Dec; 67(4):149-55. PubMed ID: 27215180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.